Ubie, a Tokyo-based healthcare startup, announced that it has closed its Series C round at $45 million by raising $19 million in an extension round. The new funding will enable Ubie to accelerate its growth and strengthen its presence in the U.S., following strong interest and traction in that market. To date, Ubie has raised $76 million in total.
The extension round money was raised from SOGO MEDICAL CO., LTD., AAIC Investment Pte. Ltd., Japan Impact Investment II Limited Partnership, and Rakuten Capital, while loans extended from the Shoko Chukin Bank, Ltd., Japan Finance Corporation, and Mizuho Bank, Ltd.
AI-powered symptom checker app and hospital SaaS products
Co-founded by medical doctor Yoshinori Abe and engineer Kubo in Tokyo in 2017, and with the mission of “guiding people to appropriate medical care with technology,” Ubie is one of the few companies in the world having direct contact with both patients and medical institutions. With AI as its core technology, the company provides AI symptom checker — as the gateway to medical care. It will also focus on expanding its business to the U.S. in order to apply the technology it has developed in Japan, one of the leading countries in the medical field.
Subsidiary set up in NY
Leveraging the Series C funding, the Japanese company established a local subsidiary in New York on October 4, 2022. This is the second overseas corporation following Singapore. The decision follows the fact that the number of users has been increasing steadily since the release of the AI symptom checker in April 2022 in the U.S. The establishment of the local subsidiary will further strengthen the partnership with U.S. pharmaceutical companies, as well as the products, including hiring local people in the U.S.
